Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.

Nagai H, Kanekawa T, Kobayashi K, Mukozu T, Matsui D, Matsui T, Kanayama M, Wakui N, Momiyama K, Shinohara M, Ishii K, Igarashi Y, Sumino Y.

Cancer Chemother Pharmacol. 2014 Feb;73(2):223-9. doi: 10.1007/s00280-013-2344-1. Epub 2013 Nov 13.

PMID:
24220937
2.

Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.

Nagai H, Miyaki D, Matsui T, Kanayama M, Higami K, Momiyama K, Ikehara T, Watanabe M, Sumino Y, Miki K.

Cancer Chemother Pharmacol. 2008 Jul;62(2):271-6. Epub 2007 Sep 26.

PMID:
17899083
3.

Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.

Godin C, Louandre C, Bodeau S, Diouf M, Saidak Z, Conte MA, Chauffert B, Barbare JC, Barget N, Trinchet JC, Ganne N, Galmiche A.

Anticancer Res. 2015 Mar;35(3):1803-8.

PMID:
25750346
4.

Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.

Nagai H, Mukozu T, Ogino YU, Matsui D, Matsui T, Wakui N, Momiyama K, Igarashi Y, Sumino Y, Higai K.

Anticancer Res. 2015 Apr;35(4):2269-77.

PMID:
25862889
5.

Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma.

Nagai H, Mukozu T, Matsui D, Kanekawa T, Kanayama M, Wakui N, Momiyama K, Shinohara M, Iida K, Ishii K, Igarashi Y, Sumino Y.

Clin Dev Immunol. 2012;2012:607851. doi: 10.1155/2012/607851. Epub 2012 May 14.

6.

Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.

Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F.

Mol Cancer Ther. 2012 Oct;11(10):2284-93. doi: 10.1158/1535-7163.MCT-12-0093. Epub 2012 Aug 17.

7.

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.

Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC.

Liver Int. 2013 Jul;33(6):950-7. doi: 10.1111/liv.12168. Epub 2013 Apr 21.

PMID:
23601249
8.

Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.

Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, Shibuya A, Minamino T, Kokubu S, Koizumi W.

Eur J Gastroenterol Hepatol. 2013 Jun;25(6):683-9. doi: 10.1097/MEG.0b013e32835d913b.

PMID:
23395995
9.

Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.

Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.

Dig Dis. 2014;32(6):733-9. doi: 10.1159/000368013. Epub 2014 Oct 29.

PMID:
25376291
10.

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.

Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De Minicis S, Bitetto D, Loretelli C, D'Anzeo M, Benedetti A, Cascinu S.

BMC Cancer. 2014 Feb 20;14:110. doi: 10.1186/1471-2407-14-110.

11.

Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.

Elleuch N, Ennaifer R, Romdhane H, Cheikh M, Hefaiedh R, Bougassas W, Ben Nejma H, BelHadj N.

Tunis Med. 2015 Jun;93(6):350-2.

12.

Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.

Barbier L, Fuks D, Pessaux P, Muscari F, Le Treut YP, Faivre S, Belghiti J.

Ann Surg Oncol. 2013 Oct;20(11):3603-9. doi: 10.1245/s10434-013-3029-z. Epub 2013 May 29.

PMID:
23715965
14.

Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.

da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J.

Med Oncol. 2014 Nov;31(11):264. doi: 10.1007/s12032-014-0264-5. Epub 2014 Oct 2.

PMID:
25273866
15.

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.

Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.

PMID:
23182599
16.

Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.

Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Díaz-Rubio E.

Clin Transl Oncol. 2013 Feb;15(2):146-53. doi: 10.1007/s12094-012-0902-3. Epub 2012 Aug 9.

PMID:
22875650
17.

Sorafenib in liver function impaired advanced hepatocellular carcinoma.

Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang XJ, Zou X, Sun L, Zhang ZC.

Chin Med Sci J. 2014 Mar;29(1):7-14.

PMID:
24698672
18.

Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.

Køstner AH, Sorensen M, Olesen RK, Grønbæk H, Lassen U, Ladekarl M.

ScientificWorldJournal. 2013;2013:931972. doi: 10.1155/2013/931972. Epub 2013 Jan 29.

19.

Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.

Tanoglu A, Karagoz E.

Asian Pac J Cancer Prev. 2014;15(2):1063. No abstract available.

20.

Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.

Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.

Oncology. 2014;87 Suppl 1:32-6. doi: 10.1159/000368143. Epub 2014 Nov 22.

PMID:
25427731
Items per page

Supplemental Content

Write to the Help Desk